FindTrial
Sign In

A preliminary study on the delivery of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) at high risk of HIV transmission through the application of a self-financed incentivized approach

A preliminary study on the delivery of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) at high risk of HIV transmission through the application of a self-financed incentivized approach

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-16009603
Enrollment
Unknown
Registered
2016-10-22
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection

Interventions

One group:HIV prevention / Daily pre-exposure prophylaxis / truvada
Truvada tablet (Tenofovir 300 mg / Emtricitabine 200 mg), 1 tablet, 30 weeks, daily

Sponsors

Stanley Ho Centre for Emerging Infectious Diseases
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. man who have sex with man (MSM); 2. 18 years old or above; 3. able to communicate in written and spoken English or Chinese; 4. inclination to engage in unprotected anal sex; 5. a history of unprotected anal sex, especially as receptive partner, within the preceding 6 months; 6. normally resident in Hong Kong; 7. willingness to partly pay for the antiretroviral for PrEP; 8. referral from an HIV counselling service.

Exclusion criteria

Exclusion criteria: 1. prisoner; 2. having any form of mental illnesses; 3. inability or refusal to give consent; 4. HIV positive; 5. known renal insufficiency with creatinine clearance <60mL/min; 6. known hepatitis B carrier.

Design outcomes

Primary

MeasureTime frame
Acceptability of PrEP;Proportion fully adherent to daily PrEP;—

Secondary

MeasureTime frame
discontinuation rate;coverage of unprotected sex;—

Countries

China

Contacts

Public ContactShui Shan Lee

Stanley Ho Centre for Emerging Infectious Diseases

sslee@cuhk.edu.hk+852 22528812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026